News & Views | Published:

Pancreatic cancer

Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer

Nature Reviews Gastroenterology & Hepatology volume 11, pages 89 (2014) | Download Citation

Targeting angiogenesis has not been successful as a treatment for pancreatic cancer. Studies using monoclonal antibodies or small molecule inhibitors of the VEGFR pathway have failed to demonstrate benefit. Now, a phase II study has shown that sorafenib does not improve the efficacy of gemcitabine plus cisplatin chemotherapy in patients with locally advanced or metastatic pancreatic adenocarcinoma.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Anti-angiogenesis therapy in pancreatic carcinoma. JOP 7, 163–173 (2006).

  2. 2.

    et al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Dig. Liver Dis. .

  3. 3.

    et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617–3622 (2010).

  4. 4.

    et al. Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV [abstract]. J. Clin. Oncol. 31 (Suppl.), 4035 (2013).

  5. 5.

    et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 12, 256–262 (2011).

  6. 6.

    et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231–2237 (2009).

  7. 7.

    et al. A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (Suppl.), 4556 (2007).

  8. 8.

    et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann. Oncol. 23, 2799–2805 (2012).

  9. 9.

    et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24, 3946–3952 (2006).

  10. 10.

    , & Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1, 12–25 (2010).

Download references

Author information


  1. Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, 800 Washington Street, Boston, MA 02111, USA.

    • Muhammad Wasif Saif


  1. Search for Muhammad Wasif Saif in:

Competing interests

The author declares no competing financial interests.

Corresponding author

Correspondence to Muhammad Wasif Saif.

About this article

Publication history



Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing